Navigation Links
New study of Concerta showed significant improvement of ADHD symptom management in adults
Date:10/26/2007

Boston, Mass., Friday Oct. 26, 2007 11:00AM Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA OROS methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.

Pharmacological treatment of children and adolescents with ADHD is clearly established but relatively less is known about the treatment of adults with ADHD, notes the studys medical director, Sally Berry, M.D., PhD., of Johnson & Johnson Pharmaceutical Research and Development, LLC. Were encouraged that the CONCERTA findings presented today -- in which CONCERTA significantly improved ADHD symptom management in adults -- can benefit the growing body of knowledge in this important therapeutic area.

The data presented today are part of a Supplemental New Drug Application (sNDA) submitted in August 2007 to the Food and Drug Administration for use of CONCERTA to treat adults with ADHD. CONCERTA is already approved for the treatment of ADHD in children and adolescents ages six to 17.

About the Study

In the study presented today, efficacy was measured as a change in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score. The results showed that CONCERTA achieved a significantly superior reduction in AISRS total score compared to placebo (p=0.012) (mean change was -10.6 1.09 for the CONCERTA group vs. -6.8 1.06 for the placebo group.

In addition, CONCERTA was significantly superior compared to placebo for the key secondary efficacy variables: change in Clinical Global Impression-Improvement (CGI-I) rating (p=0.008); change in Conners Adult ADHD Rating Scale-Self Report (CAARS-S:S) total score (p=0.029) and change in percent of subjects meeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients . Patients in the CONCERTA group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 very much or 2 much improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA and placebo groups, respectively, discontinued due to adverse events.

Todays data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.


'/>"/>

Contact: Tricia Geoghegan
tgeogheg@janus.jnj.com
609-462-8764
Golin/Harris International
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: